|Assessment Status||Rapid Review Complete|
|Indication||For the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older.|
|Rapid review commissioned||12/11/2018|
|Rapid review completed||13/12/2018|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that ozenoxacin cream not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.